Aberdeen Group plc lowered its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 73.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,126 shares of the medical technology company's stock after selling 226,075 shares during the quarter. Aberdeen Group plc's holdings in Stryker were worth $22,066,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of SYK. Bank of America Corp DE acquired a new stake in shares of Stryker during the second quarter worth approximately $1,404,284,000. Legal & General Group Plc purchased a new stake in Stryker in the 2nd quarter worth approximately $707,212,000. Jupiter Topco LLC purchased a new stake in Stryker in the 2nd quarter worth approximately $681,581,000. Corient Private Wealth LP purchased a new position in shares of Stryker during the 2nd quarter valued at $323,035,000. Finally, Flossbach Von Storch SE purchased a new position in shares of Stryker during the 2nd quarter valued at $464,506,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Stryker
In other news, Director Ronda E. Stryker sold 550,000 shares of the business's stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the sale, the director directly owned 1,701,375 shares in the company, valued at approximately $553,491,315. The trade was a 24.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Dylan Crotty sold 441 shares of the company's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares of the company's stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 4.60% of the company's stock.
Stryker Price Performance
NYSE SYK opened at $317.20 on Wednesday. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The company has a fifty day simple moving average of $293.26 and a 200 day simple moving average of $322.17. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The company has a market cap of $120.76 billion, a P/E ratio of 33.78, a P/E/G ratio of 2.13 and a beta of 0.78.
Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The firm had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same quarter last year, the business earned $3.19 EPS. The business's revenue was up 7.6% compared to the same quarter last year. On average, sell-side analysts predict that Stryker Corporation will post 14.85 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. Rothschild & Co Redburn dropped their price target on shares of Stryker from $360.00 to $336.00 in a research note on Monday, November 2nd. BMO Capital Markets reissued an "outperform" rating and set a $309.00 price objective (down from $317.00) on shares of Stryker in a research report on Friday, October 30th. JPMorgan Chase & Co. lowered their price target on Stryker from $350.00 to $340.00 and set an "overweight" rating for the company in a research note on Friday, October 30th. Stifel Nicolaus dropped their price objective on Stryker from $330.00 to $325.00 and set a "buy" rating on the stock in a report on Monday, November 2nd. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Stryker in a research report on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $342.19.
Read Our Latest Analysis on SYK
Stryker Company Profile
(
Free Report)
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company's products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
See Also
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.